Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial

by Jodi V. Mones, Michael B. Streiff, Alok A. Khorana, Gemma A. Bendheim, C. V. Damaraju, Peter Wildgoose, Paul Burton, Hanno Riess, Gerald A. Soff
Published 2021-07-01

Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial

by Alok A. Khorana, Mairéad G. McNamara, Ajay K. Kakkar, Michael B. Streiff, Hanno Riess, Ujjwala Vijapurkar, Simrati Kaul, Peter Wildgoose, Gerald A. Soff
Published 2020-04-01

Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience

by Gerald A. Soff, Jodi Mones, Cy Wilkins, Sean Devlin, Eva Haegler‐Laube, Jonathan Wills, Debra M. Sarasohn, Krishna Juluru, Michael Singer, Yimei Miao, Jeanette Batista, Simon Mantha
Published 2019-07-01